Antineoplastic Fludarabine CAS 21679-14-1 Raw Materials Powder

CAS: 21679-14-1

MF: C4H3FN2O2

Specification​: 99% min Fludarabine Powder

Sample: Fludarabine Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

MADE IN CHINA Store:https://henrikang.en.made-in-china.com/

Fludarabine Powder Usage and Synthesis :

The chemical name of fludarabine is 9‑β‑D‑ arabofuranose ‑2‑ adenosine fluoride, which is an anti-tumor drug. Fludarabine is an antimetabolic nucleoside analogue of fluorinated purine, which is highly selective to lymphocytes. It can inhibit DNA repair in cells at rest and DNA synthesis in cells at division, and can promote apoptosis of these cells. Fludarabine has shown good therapeutic effect, and is now widely used in the treatment of various blood system diseases. Especially chronic B lymphocytic leukemia.

Fludarabine Powder is an antiviral drug commonly used to treat influenza and other respiratory viral infections,  such as RS virus and parainfluenza virus. Fludarabine Raw Materials may reduce illness and shorten the duration of  illness by inhibiting viral replication.Fludarabine CAS 21679-14-1 is usually required in the early stages of infection  for optimal efficacy.

Application/Function of Fludarabine Powder:

Fludarabine is a fluorinated nucleotide analogue of adenosine arabine, which is relatively resistant to the deamination of adenosine deaminase. This drug is an effective antitumor drug which may have obvious toxic and side effects. Hematological and non-hematological toxic signs of patients should be closely monitored.

• 1. In a clinical study, fludarabine phosphate combined with penastatin (deoxycoformycin) in the treatment of CLL presented an unacceptable high rate of fatal pulmonary toxicity and is therefore not recommended for use with fludarabine phosphate.
• 2. Dipyridamole and other adenosine absorption inhibitors can reduce the therapeutic effect of fludarabine phosphate.
• 3. Clinical and in vitro studies have shown that fludarabine phosphate combined with cytarabine increases both intracellular and extracellular concentrations of Ara-CTP(the active metabolite of cytarabine) in leukemia cells. The blood concentration and metabolic rate of Ara-C were not affected.

It is mainly used to treat B-cell chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

Production method of Fludarabine Powder .

This drug is a fluorinated nucleotide analogue of adenosine, which is relatively resistant to the deamidation of adenosine deaminase. Fludarabine phosphate is rapidly dephosphorylated to 2F-ara-A, which can be taken up by cells and then phosphorylated by intracellular deoxycytidine kinase to become the active triphosphate 2F-ara-ATP.

This metabolite can inhibit DNA synthesis by inhibiting nucleotide reductase, DNA polymerase (α, δ and ε), DNA primase and DNA ligase. In addition, it can also partially inhibit RNA polymerase II thereby reducing protein synthesis.

After intravenous administration, the phosphate of this product is rapidly dephosphorylated and its substrate is taken up by lymphocytes and then rephosphorylated into the active fludarabine triphosphate. Intracellular fludarabine triphosphate peaks at 4 hours after a single dose. The product is clear from the blood picture in triphasic form.

The terminal half-life is approximately 10 to 30 hours. Most of the drug is eliminated in the urine. approximately 60% of the administered dose is excreted within 24 hours. Oral dosing of 40 mg/(m2-d) produces the same overall concentration as intravenous dosing of 25 mg/(m2-d). There are significant individual differences in the pharmacokinetics of this product.